Fred Saad
Affiliations: | Biomedical Sciences | Université de Montréal, Montréal, Canada |
Area:
Oncology, Public Health, Microbiology BiologyGoogle:
"Fred Saad"Cross-listing: PHTree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Agarwal N, Azad AA, Carles J, et al. (2025) Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. The Lancet. Oncology |
| Aprikian A, Saad F, Wywial E, et al. (2025) Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada. Journal of Medical Economics. 28: 766-777 |
| Miszczyk M, Fazekas T, Rajwa P, et al. (2025) Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis. European Urology Focus |
| Kollmannsberger C, Finelli A, Loblaw A, et al. (2025) Optimizing therapy for high-risk biochemically recurrent non-metastatic prostate cancer: Current and emerging strategies. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada |
| Barletta F, Tappero S, Morra S, et al. (2025) Impact of ISUP grade group on cancer-specific mortality in radical prostatectomy-treated prostate cancer patients with organ-confined disease. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada |
| Armstrong AJ, Sartor O, de Bono J, et al. (2025) Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562]. European Urology |
| Fay AP, Fizazi K, Matsubara N, et al. (2025) First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet. Oncology. 26: 481-490 |
| Matsubara N, Azad AA, Agarwal N, et al. (2025) First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet. Oncology. 26: 470-480 |
| Saad F, Hussain MHA, Tombal B, et al. (2025) Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary. Future Oncology (London, England). 1-14 |
| Tisseverasinghe S, Tolba M, Bahoric B, et al. (2025) Assessing the effects of prostate cancer therapies on cardiovascular health. Nature Reviews. Urology |